QSPR and QSTR analysis to explore pharmacokinetic and toxicity properties of antifungal drugs through topological descriptors.

Publication date: May 23, 2025

COVID-19 patients often develop serious fungal infections like Aspergillosis, Candidiasis, and Mucormycosis, which are treated with antifungal drugs like Amphotericin B, Posaconazole, and Isavuconazole. However, these treatments are often insufficient, leading researchers to explore drug combinations and analogs. In theoretical chemistry, a chemical molecule is converted into an isomorphic molecular graph, represented as G (V, E) by considering atom set V as vertices and bond set E as edges. Quantitative structure-activity/property/toxicity relationships (QSAR, QSPR, QSTR) modelling is a widely recognized discipline that correlates physicochemical and molecular descriptors with a drug’s bioactivity to predict its standard pharmacological properties. In this article, the aforementioned drugs, as well as some Amphotericin B analogs, with their properties, are considered for QSPR/QSTR analysis. The QSPR/QSTR analysis is carried out using linear regression between the computed topological indices (based on degree and neighbourhood degree sum) and pharmacokinetic (ADMET) and toxicity properties (LD) of these drugs. The analysis reveals a strong correlation between the topological indices and the pharmacokinetic and toxicity properties of the drugs and their analogs. These insights are crucial for advancing more effective antifungal treatments, especially for COVID-19-related infections.

Open Access PDF

Concepts Keywords
Aspergillosis ADMET
Covid Amphotericin B
Fungal Amphotericin B
Pharmacokinetic Antifungal Agents
Theoretical Antifungal Agents
Antifungal drugs
COVID-19
COVID-19 Drug Treatment
Humans
isavuconazole
LD50
Linear regression
Nitriles
Nitriles
posaconazole
Pyridines
Pyridines
QSPR analysis
Quantitative Structure-Activity Relationship
SARS-CoV-2
Topological indices
Triazoles
Triazoles

Semantics

Type Source Name
disease MESH COVID-19
disease MESH fungal infections
disease MESH Aspergillosis
disease MESH Candidiasis
disease MESH Mucormycosis
drug DRUGBANK Amphotericin B
drug DRUGBANK Posaconazole
drug DRUGBANK Isavuconazole
disease MESH infections
pathway REACTOME Immune System
disease IDO infection
disease MESH respiratory infections
disease MESH Pulmonary aspergillosis
disease MESH complications
disease MESH candidemia
drug DRUGBANK Coenzyme M
disease MESH CNS fungal infections
drug DRUGBANK Water
pathway REACTOME Metabolism
disease IDO process
disease IDO algorithm
disease MESH cancer
disease MESH dengue
drug DRUGBANK Methionine
disease IDO role
pathway REACTOME Intestinal absorption
disease MESH invasive pulmonary aspergillosis
disease MESH oral candidiasis
disease MESH systemic lupus erythematosus
pathway KEGG Systemic lupus erythematosus
drug DRUGBANK Curcumin
disease MESH Diabetes mellitus
disease MESH invasive fungal infections
disease MESH breast cancer
pathway KEGG Breast cancer
disease IDO blood
disease MESH rheumatoid arthritis
pathway KEGG Rheumatoid arthritis
pathway REACTOME Reproduction

Original Article

(Visited 1 times, 1 visits today)